Inhaled and nasal product testing and characterization

Technology class

Inhaled and nasal product testing and characterization

Methods and apparatus for testing and characterizing orally inhaled and nasal drug products

Inhaled and nasal product testing and characterization encompasses the analytical methods, instrumentation, and standardized protocols required to evaluate the critical quality attributes of orally inhaled and nasal drug products, including aerodynamic particle size distribution, delivered dose uniformity, spray pattern geometry, and plume characteristics. This mechanism underpins regulatory acceptance of all device types covered in this report—DPIs, pMDIs, SMIs, nebulizers, and nasal sprays—by providing the quantitative evidence that formulation and device performance meet specifications across manufacturing batches and throughout product shelf life.

Target siteLung or nasal
Filing growth, 2014–23−7.7% a year
Top 4 holders hold17%
Patent holders156
Effective holders73
Commercial products533

Effective holders is the inverse of the HHI (1 ÷ HHI): a measure of how concentrated patent ownership is in this class.

Technology mechanism

Testing and characterization of inhaled and nasal products relies on a suite of complementary analytical techniques specified in pharmacopeial chapters including USP <601> and Ph. Eur. 2.9.18. Aerodynamic particle size distribution, the primary determinant of lung deposition, is measured using cascade impactors such as the Andersen Cascade Impactor operating at 28.3 L/min or the Next Generation Impactor at 30–100 L/min depending on device type; these instruments fractionate aerosol particles across stages with defined cutoff diameters, enabling calculation of mass median aerodynamic diameter and fine particle fraction below 5 micrometers. Delivered dose uniformity testing employs dose collection apparatus that captures the emitted dose through a standardized induction port, with acceptance criteria typically requiring that 9 of 10 containers deliver within 75–125 percent of label claim and all within 65–135 percent. For nasal sprays, spray pattern analysis uses laser light sheet imaging to capture the two-dimensional cross-section of the spray plume at defined distances from the actuator, measuring ovality ratio and Dmax parameters, while plume geometry assessment characterizes the three-dimensional cone angle and spray width. Droplet size distribution for nasal products is determined by laser diffraction instruments operating at distances of 3–6 centimeters from the spray orifice, with D10, D50, and D90 values reported. Breath simulation systems replicate patient inhalation profiles—sinusoidal or square-wave patterns at 15–90 L/min peak inspiratory flow—to evaluate device performance under realistic use conditions, which is particularly critical for DPIs where aerosolization depends on patient effort. Cascade impactor measurements for pMDIs require coordination with actuation timing, often using automated actuator systems to ensure reproducibility. Moisture content analysis via Karl Fischer titration and particle morphology assessment through scanning electron microscopy complement aerodynamic testing to provide comprehensive formulation characterization. Real-time aerosol monitoring using optical particle counters or time-of-flight instruments enables rapid screening during development, though pharmacopeial cascade impaction remains the regulatory gold standard for batch release.

Operational footprint

Testing laboratories require controlled environmental conditions, typically 23 plus or minus 2 degrees Celsius and 50 plus or minus 5 percent relative humidity, to ensure measurement reproducibility. Cascade impactor testing demands trained analysts with expertise in apparatus assembly, stage coating to prevent particle bounce, and gravimetric analysis; a single determination including setup, actuation, disassembly, and weighing requires 2–4 hours, limiting throughput to 4–8 complete tests per analyst per day. Laser diffraction systems offer higher throughput for droplet sizing, with measurements completed in seconds, but require rigorous alignment verification and method validation. Breath simulation equipment ranges from simple vacuum pumps with flow controllers to sophisticated electronic lung simulators costing 50,000–150,000 dollars that replicate pediatric, adult, and compromised breathing patterns. Spray pattern and plume geometry analyzers represent specialized capital investments of 100,000–300,000 dollars with dedicated software for image analysis. Contract research organizations and pharmaceutical quality control laboratories serving multiple clients typically maintain the full suite of compendial equipment, while device developers may outsource specialized testing during early development. Regulatory submissions require method validation demonstrating specificity, linearity, accuracy, precision, and robustness, with validation packages often requiring 6–12 months to complete for novel products.

Maturity signals

The testing and characterization infrastructure supporting inhaled and nasal products is highly mature, with pharmacopeial methods established for decades and continuously refined through industry working groups and regulatory guidance updates. FDA guidance documents on bioavailability and bioequivalence for orally inhaled drug products, nasal sprays, and metered dose inhalers provide detailed specifications for in vitro testing requirements. Clinical trials across the commercial landscape routinely incorporate device comparison studies evaluating pharmacokinetic profiles, lung deposition via gamma scintigraphy or pharmacokinetic modeling, and patient handling assessments—as evidenced by trials comparing DPI versus pMDI performance, evaluating novel inhaler usability, and characterizing lung deposition of liposomal and powder formulations. Patent activity in this domain shows a mechanism-aligned participation pattern with moderate competitive density across 108 patents from 10 unique assignees, indicating focused innovation rather than broad fragmentation. Dominant contributors include major pharmaceutical companies with extensive inhaler portfolios alongside academic institutions advancing novel characterization methodologies; this pattern suggests that testing innovation often occurs in partnership between device developers and specialized research centers rather than through standalone instrumentation companies. White space exists in standardized methods for emerging modalities including mRNA inhalation products and complex nasal powder formulations where existing compendial approaches may require adaptation.

Challenges

Cascade impaction, while regulatory-accepted, provides only a snapshot of aerodynamic behavior under idealized conditions that may not fully predict in vivo lung deposition across diverse patient populations with varying inspiratory capacities. The labor-intensive nature of compendial testing creates bottlenecks during development and manufacturing, with batch release testing for commercial products requiring significant quality control resources. Harmonization gaps persist between FDA, EMA, and other regulatory authorities regarding acceptable in vitro methodologies, particularly for demonstrating bioequivalence of generic inhaled products where some jurisdictions accept in vitro-only approaches while others mandate pharmacokinetic or pharmacodynamic studies. Testing of combination products with digital components, such as smart inhalers with dose tracking sensors, introduces additional validation requirements for software functionality that existing pharmacopeial methods do not address. Environmental variability—temperature and humidity fluctuations during testing—can significantly affect hygroscopic formulations, requiring stringent laboratory controls that may not reflect real-world storage and use conditions. For nasal products, the anatomical variability of the nasal cavity and the lack of standardized in vitro nasal cast models complicate correlation between bench testing and clinical performance. Unlike the device mechanisms described in M1 through M4 where innovation focuses on delivery efficiency, testing methodology innovation must balance analytical rigor with practical throughput demands, and novel rapid methods face extended timelines for regulatory acceptance as alternatives to established compendial approaches.

← Back to what’s inside this report